Drug application
VIEKIRA XR (DASABUVIR SODIUM, OMBITASVIR, PARITAPREVIR and 1 more)
Drugs@FDA NDA 208624 · ABBVIE
Key facts
| Drug name | VIEKIRA XR |
|---|---|
| Active ingredients | DASABUVIR SODIUM, OMBITASVIR, PARITAPREVIR, RITONAVIR |
| Application type | NDA |
| Application number | 208624 |
| Company | ABBVIE |
| Dosage forms | TABLET, EXTENDED RELEASE, ORAL |
| Strength | EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** |
| Marketing status | Discontinued |
| Reference listed drug | Yes |
| Latest submission class | Type 3 - New Dosage Form |
| Latest submission status date | Jul 22, 2016 |
At a glance
- 1–9 Submissions
- 1–9 Supplements
- 1–9 Label versions
- 1–9 Products
- None Therapeutic equivalents
- Yes FDA letters on file
- Yes FDA reviews on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: